European Society for Medical Oncology shared on LinkedIn:
“ESMO Novel Therapies 2027: Join us in Lugano to explore how the latest advances in oncology are being translated into everyday clinical practice.
As novel therapies continue to reshape cancer care, optimizing their use requires more understanding.
It demands practical experience, collaboration, and strategies to effectively manage treatment-related toxicities while maximizing patient outcomes.
Check what is happening on Day 1 (Monday 8 March 2027):
- Antibody-drug conjugates (ADCs) in oncology
- Supportive care considerations for patients receiving ADCs
- ADC combinations and sequencing: practical considerations for patient management
Through real-world case discussions and peer-to-peer learning, participants will gain practical insights that can be applied directly in clinical practice.
Swipe through the images to discover highlights from these featured sessions and stay tuned for more updates on the scientific programme.”
ESMO Novel Cancer Therapies 2027: Programme
Other articles about ESMO on OncoDaily.
